LENZ Therapeutics Inc (NASDAQ: LENZ) on Friday, plunged -16.13% from the previous trading day, before settling in for the closing price of $46.25. Within the past 52 weeks, LENZ’s price has moved between $16.53 and $50.40.
A company in the Healthcare sector has dropped its sales by -181.63% annually for the last half of the decade. The company achieved an average annual earnings per share of -10.87%. With a float of $24.40 million, this company’s outstanding shares have now reached $28.50 million.
LENZ Therapeutics Inc (LENZ) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of LENZ Therapeutics Inc is 14.45%, while institutional ownership is 92.31%. The most recent insider transaction that took place on Sep 30 ’25, was worth 6,117,323. In this transaction 10% Owner of this company sold 132,944 shares at a rate of $46.01, taking the stock ownership to the 1,050,599 shares. Before that another transaction happened on Sep 30 ’25, when Company’s 10% Owner sold 92,030 for $46.01, making the entire transaction worth $4,234,695. This insider now owns 764,127 shares in total.
LENZ Therapeutics Inc (LENZ) Performance Highlights and Predictions
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.38 earnings per share (EPS) for the period topping the consensus outlook (set at -0.43) by 0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.77 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -10.87% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 52.23% during the next five years compared to -181.63% drop over the previous five years of trading.
LENZ Therapeutics Inc (NASDAQ: LENZ) Trading Performance Indicators
LENZ Therapeutics Inc (LENZ) is currently performing well based on its current performance indicators. A quick ratio of 20.54 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 221.27.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.90, a number that is poised to hit -0.69 in the next quarter and is forecasted to reach -2.54 in one year’s time.
